Viridian Therapeutics (VRDN) announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 clinical trials for VRDN-003 in patients with active and chronic TED, respectively. VRDN-003 is a subcutaneously delivered, half-life extended, monoclonal antibody targeting the insulin-like growth factor-1 receptor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics files automatic mixed securities shelf
- Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating
- Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
- Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment
- Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo